Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight...
Stay updated with breaking news from Leonard Ebah. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight...
Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu...
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and...
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and...
The best of people in the worst of times The Manchester Evening News has been granted rare access to Covid-19 wards at the Manchester Royal Infirmary. We met staff and patients enduring the toughest fight of their lives. 19:35, 1 MAR 2021 Updated Sam Clarke took the mask from its packet and pulled it over her face. It was a routine she had been through hundreds of times before. But this time, the instant the fabric touched her skin, she froze. The air heavy, her throat tight, she gasped desperately for breath. As a nurse, Sam knew she was having a panic attack. It would be the first of many -...